Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN1101 adjunctive therapy in adults with focal-onset epilepsy
2023-508681-15-00Phase 2Authorised
- Sponsor
- Xenon Pharmaceuticals
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of azetukalner in Focal Onset Epilepsy (3 arms), sponsored by Xenon Pharmaceuticals. Primary endpoints: Median percent change in monthly focal seizure frequency and Safety and tolerability. Planned start May 2019; status: authorised.
02
Drugs
azetukalner
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2023-508681-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508681-15-00.